TC Biopharm (Holdings) Plc (TCBPY)
OTCMKTS
· Delayed Price · Currency is USD
0.2800
-0.0400 (-12.50%)
Apr 2, 2025, 4:00 PM EST
TC Biopharm (Holdings) Company Description
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm (Holdings) Plc
| Country | United Kingdom |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Bryan Kobel |
Contact Details
Address: Maxim 1 Motherwell, ML1 4WR United Kingdom | |
| Phone | 44 14 1433 7557 |
| Website | tcbiopharm.com |
Stock Details
| Ticker Symbol | TCBPY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bryan Kobel | Chief Executive Officer |
| Martin Thorp | Chief Financial Officer |